8-K: NewAmsterdam Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

NewAmsterdam Pharma announces its Q1 2025 financial results, highlighting a strong cash position and continued clinical development of obicetrapib.

Summary

• NewAmsterdam Pharma reported its financial results for the quarter ended March 31, 2025.
• The company had $808.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025.
• Revenue for the quarter was $3.0 million, compared to $1.4 million in the same period in 2024.
• Research and Development expenses were $44.8 million, up from $42.4 million in Q1 2024.
• Selling, General and Administrative expenses increased to $27.2 million from $14.5 million in the prior year's quarter.
• The net loss for the quarter was $39.5 million, a significant decrease from the $93.8 million loss in Q1 2024.
• The company is progressing with the clinical development of obicetrapib, with an expected EMA submission in the second half of 2025 by partner Menarini.
• The PREVAIL Phase 3 CVOT remains on track.
• Additional data from BROADWAY, TANDEM, and BROOKLYN trials are expected to be presented and published over the next several months.
• NewAmsterdam appointed Adele Gulfo to the Company's Board of Directors in April 2025.
• The company will host an R&D Day on June 11, 2025, in New York City.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, increased revenue, and decreased net loss, offset by increased R&D and SG&A expenses. The progress of obicetrapib's clinical development and the upcoming R&D Day also contribute to the positive outlook.

Positives

• The company has a strong cash position of $808.5 million.
• Revenue increased to $3.0 million in Q1 2025 compared to $1.4 million in Q1 2024.
• Net loss decreased significantly to $39.5 million in Q1 2025 from $93.8 million in Q1 2024.
• The PREVAIL Phase 3 CVOT is on track.
• The company is progressing with regulatory interactions, including an expected EMA submission in the second half of 2025 by partner Menarini.
• Additional data from BROADWAY, TANDEM, and BROOKLYN trials are expected to be presented and published over the next several months, highlighting what we believe to be obicetrapibs differentiated product profile to lipid management.

Negatives

• R&D expenses increased to $44.8 million in Q1 2025 from $42.4 million in Q1 2024.
• SG&A expenses increased to $27.2 million in Q1 2025 from $14.5 million in Q1 2024.
• The company experienced a net loss of $39.5 million for the quarter.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to clinical trials, regulatory approvals, and commercialization.
• Competition from other product candidates could impact the company's business.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, could affect the company's operations.
• The company's ability to obtain sufficient supply of materials is a risk factor.

Future Outlook

The company is focused on clinical execution and investment in its commercial organization to support the potential launch of obicetrapib, with an expected EMA submission in the second half of 2025 by partner Menarini, and plans to announce additional data over the course of 2025 relating to obicetrapib and the fixed-dose combination (FDC) of obicetrapib plus ezetimibe.

Management Comments

• 'Our first quarter was marked by continued clinical execution and investment in our commercial organization to support the potential launch of obicetrapib,' said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
• Dr. Davidson continued, 'In addition, the data recently presented at EAS and published in the New England Journal of Medicine and The Lancet highlight obicetrapibs differentiated product profile for the potential treatment of lipid management, and we are eager to continue to share additional data from our three pivotal Phase 3 trials, particularly regarding obicetrapibs impact on major adverse cardiac events (MACE), at prominent medical conferences and journal publications.'

Industry Context

NewAmsterdam Pharma is developing obicetrapib to address the unmet need for safe and effective LDL-C lowering therapies in patients at risk of cardiovascular disease, a leading cause of death globally, despite the availability of existing lipid-lowering therapies.

Comparison to Industry Standards

• NewAmsterdam Pharma is focused on developing obicetrapib, a CETP inhibitor, to lower LDL-C levels, similar to how Amgen's Repatha (evolocumab) and Sanofi's Praluent (alirocumab) (PCSK9 inhibitors) work, but through a different mechanism.
• Unlike statins, which are the first-line treatment for high cholesterol, obicetrapib aims to provide an alternative or complementary therapy for patients who do not achieve sufficient LDL-C reduction with statins or cannot tolerate them.
• The company's focus on cardiovascular outcomes trials (CVOTs) like PREVAIL is consistent with industry standards for demonstrating the clinical benefit of LDL-C lowering therapies, similar to trials conducted for PCSK9 inhibitors and other cardiovascular drugs.
• The partnership with Menarini for commercialization in Europe is a common strategy in the pharmaceutical industry to leverage regional expertise and infrastructure.

Management Changes

Stakeholder Impact

• Shareholders: The strong cash position and progress in clinical trials are positive for shareholders.
• Employees: Increased investment in commercial organization and R&D may create opportunities for employees.
• Patients: The development of obicetrapib aims to provide a new treatment option for patients with elevated LDL-C and cardiovascular disease.
• Partners: The partnership with Menarini for commercialization in Europe is expected to benefit both companies.

Next Steps

• Presenting and publishing additional data from BROADWAY, TANDEM, and BROOKLYN trials.
• Progressing with regulatory interactions, including an expected EMA submission in the second half of 2025 by partner Menarini.
• Hosting an R&D Day event on June 11, 2025, in New York City.
• Continuing the PREVAIL Phase 3 CVOT.

Key Dates

Keywords

Obicetrapib, Cardiovascular Disease, LDL-C, CETP Inhibitor, Clinical Trials, Financial Results, NewAmsterdam Pharma, Menarini, PREVAIL, Revenue, Net Loss, R&D Expenses, Regulatory Approval